WO2011065350A1 - ヒドロキシアルキルセルロース微粒子 - Google Patents
ヒドロキシアルキルセルロース微粒子 Download PDFInfo
- Publication number
- WO2011065350A1 WO2011065350A1 PCT/JP2010/070867 JP2010070867W WO2011065350A1 WO 2011065350 A1 WO2011065350 A1 WO 2011065350A1 JP 2010070867 W JP2010070867 W JP 2010070867W WO 2011065350 A1 WO2011065350 A1 WO 2011065350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyalkyl cellulose
- fine particles
- aqueous solution
- hydroxyalkyl
- producing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/02—Oxycellulose; Hydrocellulose; Cellulosehydrate, e.g. microcrystalline cellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/08—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with hydroxylated hydrocarbon radicals; Esters, ethers, or acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
- C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/08—Cellulose derivatives
- C08J2301/26—Cellulose ethers
- C08J2301/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/14—Polymer mixtures characterised by other features containing polymeric additives characterised by shape
- C08L2205/18—Spheres
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present invention relates to hydroxyalkyl cellulose fine particles, a method for producing the same, and a solid preparation containing the fine particles.
- a direct tableting method or a granule compression method is known as a method for producing a solid preparation.
- the direct tableting method has a shorter process than the granule compression method with granulation operation, and is excellent in terms of validation.
- the direct tableting method is easily affected by powder characteristics, so appropriate control of the powder properties of the active ingredient and additives, selection of manufacturing equipment and processes, etc. are important from the viewpoint of stable tablet production. is there.
- a particularly big problem in the direct tableting method is compression moldability. If the compression moldability is low, the tablet obtained by molding has low hardness and high friability. As a result, the tablets are easily damaged during the packaging / filling process and the transportation process.
- a binder is used to enhance compression moldability. However, there are not many satisfactory binders that can be used in the dry direct tableting method and can exert the binding force with a small amount of addition.
- hydroxyalkyl cellulose is used, for example, as a binder or molding substrate added to solid preparations such as pharmaceutical granules and tablets, as a binder for producing ceramics, as a film or coating agent, or as a viscosity modifier. It is used as an agent, dispersant, or adhesive. Hydroxyalkyl cellulose is usually supplied in the form of particles.
- a spray drying method has been reported as a method for preparing hydroxypropyl cellulose particles. When the spray drying method is used, it is necessary to prepare particles from a dilute solution in order to obtain target particles, which has a problem in terms of productivity.
- Patent Document 1 discloses hydroxypropylcellulose particles having a particle diameter of 1 to 150 ⁇ m for use in an adhesive layer of a patch.
- Patent Document 2 and Patent Document 3 disclose low-substituted hydroxypropylcellulose particles having a volume average particle diameter of 25 ⁇ m or less measured by a dry laser diffraction method for use in solid preparations. These hydroxypropylcellulose particles are prepared by fluidized bed granulation of a powder obtained by a vibration mill or the like.
- JP-A-6-199660 Japanese Patent Laid-Open No. 2001-200001 JP 2001-322927 A JP 2008-133258 A Japanese Patent Publication No. 6-33939 JP 2006-90571 A JP 2002-207030 A
- Patent Document 4 since there is another prior art document (for example, Patent Document 4) that teaches that when the average particle size is less than 10 ⁇ m, the agglomeration property may increase and the fluidity of the particles may decrease, There was no attempt to produce hydroxyalkyl cellulose fine particles having a diameter of less than 10 ⁇ m and to actually use them in solid preparations and the like. Further, most of the hydroxyalkyl cellulose particles obtained by a pulverizer such as a mill were in the form of angular flakes or irregular shapes. Such conventional hydroxyalkyl cellulose particles do not have sufficient compression characteristics in tablet production by the direct compression method, and the tensile strength and disintegration of the resulting tablets are not always satisfactory. Therefore, an object of one embodiment of the present invention is to provide hydroxyalkyl cellulose fine particles suitable for obtaining a solid preparation excellent in tensile strength and disintegration.
- the present inventors generate a pulse shock wave, and supply the hydroxyalkyl cellulose aqueous solution to the generation region of the pulse shock wave to pulverize and dry the hydroxyalkyl cellulose aqueous solution.
- a method for producing hydroxyalkyl cellulose fine particles has been found. It has been found that hydroxyalkyl cellulose fine particles having a volume average particle diameter of 0.1 ⁇ m or more and less than 15 ⁇ m can be easily obtained by this production method.
- the method for producing hydroxyalkyl cellulose fine particles according to the present invention includes the following aspects.
- a method for producing fine hydroxyalkyl cellulose particles which comprises generating a pulse shock wave, supplying a hydroxyalkyl cellulose aqueous solution to the generation region of the pulse shock wave, and crushing and drying the hydroxyalkyl cellulose aqueous solution.
- ⁇ 3> The method for producing hydroxyalkyl cellulose fine particles according to ⁇ 1> or ⁇ 2>, wherein the obtained hydroxyalkyl cellulose fine particles have a spherical shape.
- the hydroxyalkyl cellulose supplied as an aqueous solution has the viscosity at 20 ° C. of the 2% aqueous solution in the range of 2.0 to 20.0 mPa ⁇ s, any one of the above ⁇ 1> to ⁇ 3>
- ⁇ 5> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 1> to ⁇ 4>, wherein the hydroxyalkyl cellulose supplied as an aqueous solution has a hydroxyalkyl group content in the range of 40 to 80% by weight.
- ⁇ 6> The method for producing hydroxyalkyl cellulose fine particles according to any one of ⁇ 1> to ⁇ 5>, wherein the hydroxyalkyl cellulose supplied as an aqueous solution is hydroxypropyl cellulose.
- a method for producing hydroxyalkyl cellulose fine particles comprising supplying a hydroxyalkyl cellulose aqueous solution as a raw material to a pulverizing and drying apparatus having a gas adjusting means for setting a gas particle Reynolds number so as to be changeable and pulverizing and drying the raw material.
- ⁇ 9> The method for producing fine hydroxyalkyl cellulose particles according to ⁇ 7> or ⁇ 8>, wherein the concentration of the aqueous hydroxyalkyl cellulose solution is 1 to 5% by weight.
- ⁇ 10> The method for producing hydroxyalkyl cellulose fine particles according to any one of ⁇ 7> to ⁇ 9>, wherein the obtained hydroxyalkyl cellulose fine particles have a spherical shape.
- the hydroxyalkyl cellulose supplied as an aqueous solution has a viscosity of 2% aqueous solution at 20 ° C.
- any one of the above ⁇ 7> to ⁇ 10> A method for producing the hydroxyalkyl cellulose fine particles described in 1.
- ⁇ 12> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 7> to ⁇ 11>, wherein the hydroxyalkyl cellulose supplied as an aqueous solution has a hydroxyalkyl group content in the range of 40 to 80% by weight.
- ⁇ 13> The method for producing hydroxyalkyl cellulose fine particles according to any one of ⁇ 7> to ⁇ 12>, wherein the hydroxyalkyl cellulose supplied as an aqueous solution is hydroxypropyl cellulose.
- the hydroxyalkyl cellulose fine particles according to the present invention include the following embodiments. ⁇ 14> Hydroxyalkyl cellulose fine particles obtained by the production method according to any one of ⁇ 1> to ⁇ 6>. ⁇ 15> Hydroxyalkyl cellulose fine particles obtained by the production method according to any one of ⁇ 7> to ⁇ 13>. ⁇ 16> Hydroxyalkyl cellulose fine particles having a volume average particle diameter of 0.1 ⁇ m or more and less than 15 ⁇ m. ⁇ 17> The hydroxyalkyl cellulose fine particles according to ⁇ 16>, wherein the volume average particle diameter is 0.1 ⁇ m or more and less than 10 ⁇ m.
- ⁇ 18> The hydroxyalkyl cellulose fine particles according to ⁇ 16> or ⁇ 17>, wherein the shape is spherical. ⁇ 19> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 16> to ⁇ 18>, wherein the viscosity of a 2% aqueous solution at 20 ° C. is in the range of 2.0 to 20.0 mPa ⁇ s. ⁇ 20> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 16> to ⁇ 18>, wherein the viscosity of a 2% aqueous solution at 20 ° C. is in the range of 2.0 to 10.0 mPa ⁇ s.
- ⁇ 21> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 16> to ⁇ 20>, wherein the hydroxyalkyl group content is in the range of 40 to 80% by weight.
- ⁇ 22> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 16> to ⁇ 21>, wherein the hydroxyalkylcellulose is hydroxypropylcellulose.
- ⁇ 23> The hydroxyalkyl cellulose fine particles according to any one of ⁇ 14> to ⁇ 22>, which are used in a solid preparation.
- this invention includes the following aspects.
- a solid preparation comprising the hydroxyalkyl cellulose fine particles according to any one of ⁇ 14> to ⁇ 22>.
- An orally disintegrating tablet comprising the hydroxyalkyl cellulose fine particles according to any one of ⁇ 14> to ⁇ 22>.
- a method for producing a solid preparation comprising mixing the main drug and the hydroxyalkyl cellulose fine particles according to any one of ⁇ 14> to ⁇ 22>, and tableting the mixture.
- hydroxyalkyl cellulose fine particles having a volume average particle diameter of less than 15 ⁇ m can be easily obtained.
- the hydroxyalkyl cellulose fine particles of the present invention are suitably used for the production of solid preparations such as tablets by the direct compression method or the like.
- solid preparations such as tablets by the direct compression method or the like.
- the tensile strength of the solid preparation is increased and the disintegration variation due to variations in compression pressure is extremely reduced.
- the hydroxyalkyl cellulose fine particles of the present invention are used, the binding force is increased and the disintegration time of the solid preparation can be prolonged, so that sustained release can be easily imparted to the preparation.
- FIG. 1 is a view showing a scanning electron micrograph of hydroxypropylcellulose fine particles obtained from a 2% aqueous solution in Example 1.
- FIG. 4 is a view showing a scanning electron micrograph of hydroxypropyl cellulose fine particles obtained from a 10% aqueous solution in Example 3.
- FIG. 4 is a view showing a scanning electron micrograph of hydroxypropyl cellulose fine particles obtained from a 20% aqueous solution in Example 3.
- Example 4 It is a figure which shows the scanning electron micrograph of the hydroxypropyl cellulose microparticles
- 2 is a view showing a scanning electron micrograph of hydroxypropylcellulose fine particles obtained in Comparative Example 1.
- FIG. 4 is a view showing a scanning electron micrograph of hydroxypropylcellulose fine particles obtained in Comparative Example 2.
- FIG. It is a figure which shows the hardness and disintegration time of the tablet containing the lactose / corn starch obtained in Example 6, Example 7, and Comparative Example 3. It is a figure which shows the particle size distribution of the hydroxypropyl cellulose fine particle SSL2.
- the method for producing hydroxyalkyl cellulose fine particles of the present invention includes generating a pulse shock wave, supplying a hydroxyalkyl cellulose aqueous solution to the pulse shock wave generation region, and crushing and drying the hydroxyalkyl cellulose aqueous solution.
- a pulverizing and drying apparatus having a pulse combustor and a raw material supply port arranged near the outlet of the exhaust pipe is preferably used.
- a pulverizing / drying apparatus further having a gas adjusting means for setting the Reynolds number to be changeable is particularly preferably used.
- the hydroxyalkyl cellulose used in the present invention is obtained, for example, by allowing sodium hydroxide to act on the raw material cellulose to obtain alkali cellulose, and then subjecting the alkali cellulose and alkylene oxide to a substitution reaction. After the substitution reaction, an acid such as acetic acid or hydrochloric acid can be added to the reaction solution to neutralize sodium hydroxide, and then purified. By this substitution reaction, a part or all of —OH groups in the glucose ring unit of cellulose are substituted with —O— (R—O) m —H groups.
- R represents a divalent alkyl group.
- m is a natural number of 1 or more.
- alkylene oxide used in the substitution reaction examples include ethylene oxide and propylene oxide. Of these, propylene oxide is preferably used in the present invention. When a substitution reaction is performed using propylene oxide, hydroxypropyl cellulose is obtained.
- the hydroxyalkyl cellulose supplied as an aqueous solution preferably has a hydroxyalkyl group content in the range of 40 to 80% by weight, and more preferably in the range of 53 to 78% by weight.
- the hydroxyalkyl cellulose is preferably hydroxypropyl cellulose.
- the hydroxyalkyl cellulose supplied as an aqueous solution preferably has a viscosity of 2% aqueous solution at 20 ° C. in the range of 2.0 to 20.0 mPa ⁇ s, and in the range of 2.0 to 10.0 mPa ⁇ s. More preferably.
- the concentration of the aqueous hydroxyalkyl cellulose solution supplied to the pulse shock wave generation region is preferably 1 to 30% by weight, more preferably 1 to 20% by weight, and 1 to 10% by weight. Is more preferably 1 to 5% by weight.
- a pulse shock wave (hereinafter also referred to as “pulse jet” or “nonlinear wave”) is a wave of ultra high sound pressure generated with combustion in a pulse combustor.
- This ultra high sound pressure wave is usually over 150 dB.
- the pulse combustor has a combustion chamber and an exhaust pipe. Air and fuel are respectively supplied to the combustion chamber through supply pipes to create an air-fuel mixture.
- the spark plug ignites the mixture in the combustion chamber.
- Combustion gas pressure increases the combustion gas pressure, and the high-pressure gas is ejected from the exhaust pipe at high speed. After the end of combustion, it continues to erupt due to inertia.
- New air and fuel are sucked into the combustion chamber that has become negative pressure due to the ejection of the combustion gas, and the high-temperature combustion gas in the exhaust pipe flows back into the combustion chamber.
- the temperature of the pulse combustor rises and the temperature of the combustion gas becomes sufficiently high due to the continuation of operation, the air-fuel mixture newly sucked into the combustion chamber starts self-ignition by the backflowing combustion gas, and the pulse combustor Even without using a spark plug, the so-called “pulse combustion” that continues to explode at hundreds to several hundred times per second is continued.
- a raw material supply port is provided in the vicinity of the outlet of the exhaust pipe of the pulse combustor, that is, near or at the end of the exhaust pipe, and a hydroxyalkyl cellulose aqueous solution as a material to be dried is supplied from the raw material supply port,
- the material to be dried is pulverized by the action, and is solid-liquid separated and dried.
- a pulse shock wave is accompanied by a high sound pressure wave and hot air by combustion. As a result, the material to be dried is dispersed into fine particles, and at the same time, the air boundary layer on the surface is broken or moisture near the surface is stripped off, so that the material to be dried can be instantly dried.
- This pulse shock wave is also described in Patent Document 5 and Patent Document 6.
- the “particle Reynolds number” is a dimensionless quantity that represents the ratio between the viscous force exerted by the gas and the inertial force of the gas based on the velocity difference between the particles and the surrounding gas.
- the raw material supply mode includes, for example, an injection pressure when the raw material is injected and supplied from a nozzle, a pressure and an amount of air injected together with the raw material, a raw material particle diameter (primary particle diameter) determined by the injection, etc. including.
- the gas adjusting means for setting the particle Reynolds number to be changeable is not particularly limited as long as it can change the fuel supply amount, the primary air amount, the secondary air amount, the raw material supply amount, or the raw material supply mode.
- the exhaust gas temperature in the region where the hydroxyalkyl cellulose aqueous solution is supplied is preferably in the range of 50 to 100 ° C., more preferably in the range of 70 to 90 ° C. If the exhaust gas temperature is too high, the hydroxyalkyl cellulose tends to be thermally deteriorated. If the exhaust gas temperature is too low, the efficiency of pulverization and drying tends to decrease.
- the volume average particle diameter of the hydroxyalkyl cellulose fine particles of the present invention is preferably 0.1 ⁇ m or more and less than 15 ⁇ m, more preferably 0.1 ⁇ m or more and less than 10 ⁇ m, and further preferably 1 ⁇ m or more and 9 ⁇ m or less.
- the shape of the hydroxyalkyl cellulose fine particles of the present invention is not particularly limited, but is preferably a spherical shape or a shape in which it is crushed, that is, a shape having almost no angular portions and a rounded shape as a whole.
- the volume average particle size is obtained by measuring using a laser diffraction particle size distribution analyzer (for example, “LDSA-2400” manufactured by East Japan Computer Co., Ltd.) under the conditions of air pressure of 3.0 kgf / cm 2 and focal length of 100 mm. It is the value of the particle size D 50 of the integrated value 50% in the obtained particle size distribution.
- the particle shape can be observed with a scanning electron microscope (for example, “JSM-7330” manufactured by JEOL Ltd.).
- the hydroxyalkyl cellulose fine particles of the present invention preferably have a hydroxyalkyl group (— (R—O) m —H) content in the range of 40 to 80% by weight, and in the range of 53 to 78% by weight. Is more preferable.
- a hydroxyalkyl group (— (R—O) m —H) content in the range of 40 to 80% by weight, and in the range of 53 to 78% by weight. Is more preferable.
- a solid preparation excellent in tensile strength and disintegration is easily obtained.
- the hydroxyalkyl group content decreases, the particle shape tends to be closer to a sphere.
- content of a hydroxyalkyl group can be calculated
- the hydroxyalkyl cellulose fine particles are preferably hydroxypropyl cellulose fine particles.
- the hydroxyalkyl cellulose fine particles of the present invention preferably have a viscosity of 2% aqueous solution at 20 ° C. in the range of 2.0 to 20.0 mPa ⁇ s, and in the range of 2.0 to 10.0 mPa ⁇ s. Is more preferable.
- the viscosity is an index representing the degree of polymerization of hydroxyalkyl cellulose. When the viscosity is in the above range, workability when obtaining granules and tablets is improved. The higher the viscosity, the slightly higher the tensile strength of the resulting solid preparation tends to be. The lower the viscosity, the shorter the disintegration time of the resulting solid preparation.
- the hydroxyalkyl cellulose fine particles of the present invention produce ceramics as a binder or molding substrate added to solid preparations such as granules and tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets).
- solid preparations such as granules and tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets).
- a binding agent it can be used as a film, a coating agent, a viscosity modifier, a dispersant, an adhesive, and the like.
- the hydroxyalkyl cellulose fine particles of the present invention are preferably used for solid preparations such as granules and tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets), and a dry direct compression method. It is particularly preferable to use it in a solid preparation obtained by
- the solid preparation of the present invention comprises the hydroxyalkyl cellulose fine particles of the present invention having the characteristics as described above.
- the solid preparation includes granules, tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, and orally disintegrating tablets), and preferably tablets (sugar-coated tablets, film-coated tablets, sublingual tablets, oral cavity). Including disintegrating tablets).
- solid preparations contain the main drug as a medicinal ingredient, and further include excipients, binders, disintegrants, lubricants, sustained release agents, base materials, colorants, pH adjusters, pH Additives such as buffers, surfactants, stabilizers, acidulants, fragrances, fluidizing agents, cooling agents, sweeteners, umami ingredients, and sweetness enhancers are included as necessary.
- the hydroxyalkyl cellulose fine particles are mainly contained in the solid preparation as having a function as a binder or a base material.
- Examples of the main drug include pharmaceuticals, agricultural chemicals, health food ingredients, and the like.
- examples of drugs include analgesics, antipyretic analgesics, headache treatments, antitussives, expectorants, sedatives, antispasmodics, antihistamines, antiallergic agents, antiplasmin agents, bronchodilators, asthma treatments, diabetes treatments , Liver disease treatment agent, ulcer treatment agent, gastritis treatment agent, healthy stomach digestive agent, gastrointestinal motility activator, hypertension treatment agent, angina pectoris treatment agent, antihypertensive agent, hypotension treatment agent, hyperlipidemia treatment agent , Hormonal agents, antibiotics, antiviral agents, sulfa drugs, anti-inflammatory agents, neuropsychiatric agents, intraocular pressure-lowering agents, antiemetics, antidiarrheals, gout treatment agents, arrhythmia treatment agents, vasoconstrictors, digestive agents, sleep or Hypnotic induction (induction) agent, sympathetic blocking agent, anemia
- the solid preparation of the present invention includes antibacterial agents, antiviral agents, fungicides, acaricides, insecticides, nematicides, rodenticides, herbicides, plant growth regulators, fertilizers, safeners and the like.
- the health food component is not limited as long as it is a component formulated for the purpose of enhancing health.
- excipients that can be contained other than hydroxyalkyl cellulose include, for example, oligosaccharides (for example, lactose), saccharides, starch, modified starch, sugar alcohols (for example, mannitol, sorbitol, xylitol, lactitol),
- examples include inorganic salts, calcium sulfate, aluminum and magnesium silicate complexes and oxides.
- inorganic salt excipients include phosphates or sulfates such as dicalcium phosphate dihydrate.
- binders other than hydroxyalkylcellulose include povidone, lactose, starch, modified starch, saccharides, gum arabic, tragacanth gum, guar gum, pectin, wax binder, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, copolyvidone. , Gelatin, sodium alginate and the like.
- disintegrants other than hydroxyalkylcellulose examples include croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycolate, corn starch, and low-substituted hydroxypropylcellulose.
- Lubricants that can be contained in addition to hydroxyalkyl cellulose include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium stearyl fumarate, sucrose fatty acid Examples thereof include stearic acid, palmitic acid, myristic acid, oleic acid, lauric acid, behenic acid, erucic acid, and the like.
- sustained-release agents other than hydroxyalkyl cellulose include sodium alginate, carboxyvinyl polymer; aminoalkyl methacrylate copolymer RS [Eudragit RS (trade name), Rohm Pharma), ethyl acrylate / methacrylic acid Examples thereof include acrylic polymer such as methyl copolymer suspension [Eudragit NE (trade name), Rohm Pharma Co., Ltd.].
- Examples of the base material that can be contained in addition to hydroxyalkyl cellulose include sugar coating base, water-soluble film coating base, enteric film coating base, sustained-release film coating base, and the like.
- sugar coating base sucrose is used, and examples thereof further include talc, precipitated calcium carbonate, calcium phosphate, calcium sulfate, gelatin, gum arabic, polyvinylpyrrolidone, and pullulan.
- Examples of the water-soluble film coating base include polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft copolymer, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer, polyvinylpyrrolidone, macrogol and the like. Synthetic polymers; polysaccharides such as pullulan.
- Examples of the enteric film coating base include acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD, and methacrylic acid copolymer S; natural products such as shellac.
- Examples of the sustained-release film coating base include aminoalkyl methacrylate copolymer RS and acrylic acid derivatives such as ethyl acrylate / methyl methacrylate / copolymer emulsion.
- any pH adjuster that is usually used in the field of pharmaceutical technology can be used, for example, inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, acetic acid, Examples thereof include organic acids such as succinic acid, fumaric acid, malic acid, oxalic acid, lactic acid, glutaric acid, salicylic acid and tartaric acid, or salts thereof.
- inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, acetic acid
- organic acids such as succinic acid, fumaric acid, malic acid, oxalic acid, lactic acid, glutaric acid, salicylic acid and tartaric acid, or salts thereof.
- pH buffering agents that can be contained in addition to hydroxyalkyl cellulose include amine buffering agents and carbonate buffering agents.
- surfactants that can be contained in addition to hydroxyalkyl cellulose include sodium lauryl sulfate, polysorbate 80, hydrogenated oil, polyoxyethylene (160) polyoxypropylene (30) glycol, and the like.
- stabilizers examples include tocopherol, tetrasodium edetate, nicotinamide, and cyclodextrins.
- acidulants that can be contained in addition to hydroxyalkyl cellulose include citric acid, tartaric acid, malic acid, ascorbic acid and the like.
- Examples of the fluidizing agent that can be contained in addition to hydroxyalkyl cellulose include light anhydrous silicic acid, hydrous silicon dioxide, and talc.
- Examples of the refreshing agent that can be contained in addition to hydroxyalkyl cellulose include terpene compounds (such as monoterpene alcohol) such as menthol, camphor, and borneol.
- Sweeteners that can be contained in addition to hydroxyalkyl cellulose include artificial and natural sweeteners such as aspartame, acesulfame potassium, saccharin, saccharin sodium, sucralose, sugar sweeteners (e.g., xylose, ribose, glucose, mannose, galactose, fructose, Examples include dextrose, sucrose, maltose, partially hydrolyzed starch (eg, maltitol syrup), corn syrup (solid), and sugar alcohols (eg, sorbitol, xylitol, mannitol, glycerin) and combinations thereof.
- artificial and natural sweeteners such as aspartame, acesulfame potassium, saccharin, saccharin sodium, sucralose, sugar sweeteners (e.g., xylose, ribose, glucose, mannose, galactose, fructose, Examples include dextrose, sucrose, maltose,
- Examples of the umami component that can be contained in addition to hydroxyalkyl cellulose include glutamic acid, inosinic acid, and salts thereof.
- sweetness enhancers examples include sodium chloride, potassium chloride, organic acid salts, and phosphates.
- the content of the hydroxyalkyl cellulose fine particles used in the solid preparation of the present invention is not particularly limited, but is preferably 0.5 to 15% by weight and more preferably 1 to 10% by weight in the solid preparation. .
- the method for producing the solid preparation is not particularly limited.
- an excipient or a disintegrant is added to and mixed with the main agent, a binder (hydroxyalkyl cellulose fine particles) is kneaded with this, granulated with a granulator, etc., then dried and sized, and stearic acid is added thereto.
- a method of tableting this mixture by mixing a lubricant such as magnesium (wet granulation tableting method, dry granulation tableting method); mixing the active ingredient, excipient and base material (hydroxyalkyl cellulose fine particles);
- a method of mixing a lubricant with this and tableting the mixture (dry direct tableting method); Among these, the dry direct tableting method and the dry granule tableting method are preferable in the present invention.
- mixture A 200 mg is filled into a 8 mm diameter mortar and compressed using a tableting process analyzer (“Tab-All” manufactured by Okada Seiko Co., Ltd.) under the conditions of a compression pressure of 200 MPa and a compression speed of 10 spm. Yield pressure was determined. Tablet A was obtained in this test.
- TS 2P / ( ⁇ DT)
- MPa tablet hardness
- N tablet hardness
- ⁇ the circumference
- D the tablet diameter (mm)
- T the tablet thickness (mm).
- Example 1 (Preparation of hydroxyalkyl cellulose fine particles) Hydroxypropylcellulose bulk suitable for Japanese Pharmacopoeia (2% aqueous solution with a viscosity of 6.0-10.0 mPa ⁇ s at 20 ° C; “HPC L” manufactured by Nippon Soda Co., Ltd.) dissolved in water, 1%, 2% 5% and 10% aqueous solutions were obtained, respectively.
- the bulk powder of hydroxypropylcellulose HPCL was indefinite with a volume average particle size of 103.6 ⁇ m (see FIG. 12).
- the hydroxypropylcellulose aqueous solution was supplied to a pulverizing and drying apparatus having a pulse combustor (“Hi-Palcon” manufactured by Okawara Chemical Co., Ltd.), and pulverized and dried by applying a pulse jet to the aqueous solution.
- the exhaust gas temperature in the region to which the aqueous solution was supplied was set to 80 ° C.
- hydroxypropyl cellulose fine particles were obtained. All of these fine particles were slightly flat and spherical (see FIG. 13).
- the particle diameters D 16 , D 50 , and D 84 of the fine particles were as shown in Table 1. Since the viscosity at 20 ° C. of the 2% aqueous solution of the obtained hydroxypropylcellulose fine particles was the same as that of the raw powder, it can be seen that there was no thermal deterioration of the hydroxypropylcellulose itself during the drying process.
- Example 2 Except for changing the 2% aqueous solution of hydroxypropylcellulose in Example 1 to a 2% aqueous solution of hydroxypropylcellulose (2% aqueous solution having a viscosity of 3.0 to 5.9 mPa ⁇ s at 20 ° C .; “HPC SL” manufactured by Nippon Soda Co., Ltd.) Produced hydroxypropylcellulose fine particles by the same method as in Example 1.
- the particle diameters D 16 , D 50 , and D 84 of the fine particles were as shown in Table 2.
- the fine particles had a slightly flat spherical shape.
- the viscosity at 20 ° C. of a 2% aqueous solution of fine particles was the same as the bulk powder.
- the bulk powder of hydroxypropylcellulose HPC SL had an irregular shape with a volume average particle diameter of 83.3 ⁇ m.
- Example 3 The same procedure as in Example 1 was used, except that 10% and 20% aqueous solutions of hydroxypropylcellulose (2% aqueous solution viscosity at 20 ° C. 6.0-10.0 mPa ⁇ s; Nippon Soda Co., Ltd. “HPC L”) were used. Thus, hydroxypropylcellulose fine particles were obtained. The particle diameters D 16 , D 50 , and D 84 of the fine particles were as shown in Table 2. These fine particles had a slightly flat spherical shape (see FIGS. 14 and 15). The viscosity at 20 ° C. of a 2% aqueous solution of fine particles was the same as the bulk powder.
- 10% and 20% aqueous solutions of hydroxypropylcellulose 2% aqueous solution viscosity at 20 ° C. 6.0-10.0 mPa ⁇ s; Nippon Soda Co., Ltd. “HPC L”
- Example 4 The hydroxypropyl cellulose 20% aqueous solution in Example 3 was replaced with a 20% aqueous solution of hydroxypropyl cellulose (2% aqueous solution viscosity at 20 ° C. of 2.0 to 2.9 mPa ⁇ s; “HPC SSL” manufactured by Nippon Soda Co., Ltd.). Produced hydroxypropyl cellulose fine particles by the same method as in Example 3. The particle diameters D 16 , D 50 , and D 84 of the fine particles were as shown in Table 3. The fine particles were slightly flat and spherical (see FIG. 16). The viscosity at 20 ° C. of a 2% aqueous solution of fine particles was the same as the bulk powder. The bulk powder of hydroxypropylcellulose HPC SSL had an angular irregular shape.
- Comparative Example 1 A 1% aqueous solution of hydroxypropylcellulose (2% aqueous solution at a viscosity of 6.0 to 10.0 mPa ⁇ s at 20 ° C .; “HPC L” manufactured by Nippon Soda Co., Ltd.) was dried at 150 ° C. by a spray drying method. By this drying, hydroxypropylcellulose SD1 was obtained. The shape of SD1 was as shown in FIG. The particle diameters D 16 , D 50 , and D 84 of SD1 were as shown in Table 3.
- Comparative Example 2 Hydroxypropyl cellulose SD2 was obtained in the same manner as in Comparative Example 1 except that the aqueous solution concentration was changed to 2% and the drying temperature in the spray drying method was changed to 180 ° C.
- the shape of SD2 was as shown in FIG.
- D 16 , D 50 , and D 84 are as shown in Table 3.
- L Hydroxypropyl cellulose bulk HPC L
- SLM Hydroxypropyl cellulose bulk HPC SL
- L10 Hydroxypropyl cellulose fine particles having a volume average particle diameter of 11.6 ⁇ m
- L20 hydroxypropylcellulose bulk HPC SSL
- SSL Hydroxypropyl cellulose fine particles having a volume average particle diameter of 13.3 ⁇ m obtained in Example 4
- SD1 hydroxypropylcellulose
- SD2 hydroxypropylcellulose
- a tablet using hydroxypropylcellulose (SD2) obtained by a spray drying method which is a conventional general drying method, has a higher tensile strength than a tablet using the raw powder as it is.
- the tensile strength is considerably lower than that of the tablet using the hydroxypropyl cellulose fine particles (LM) of the present invention.
- FIGS. 8 and 9 it can be seen that the strength and disintegration time of the tablet can be adjusted by the viscosity of the 2% aqueous solution at 20 ° C. and the concentration of the aqueous solution supplied for pulverization and drying.
- Example 5 3% by weight of hydroxypropylcellulose fine particles (LM), 0.5% by weight of silica (“Silysia 350” manufactured by Fuji Silysia Chemical), 1% by weight of magnesium stearate, 10% by weight, 15% by weight of crospovidone (disintegrant) 20% by weight, and 85.5% by weight, 80.5% by weight, and 75.5% by weight of erythritol were mixed thoroughly to obtain mixtures B-1, B-2, and B-3, respectively. Tablets B-1, B-2, and B-3 were obtained in the same manner as the manufacturing method for tablet A, except that the mixture B-1, B-2, and B-3 were used. About the said tablet, the tensile strength of the tablet was calculated
- Example 6 and Comparative Example 3 10% by weight of hydroxypropyl cellulose, 63% by weight of lactose ("Dilactoose S” manufactured by Freund Sangyo Co., Ltd.), 27% by weight of corn starch ("Corn Starch W” manufactured by Nippon Shokuhin Kako Co., Ltd.), and 0.5% by weight of magnesium stearate (outside Mixture C) was thoroughly mixed to obtain a mixture C.
- Tablet C was obtained by the same method as the manufacturing method of tablet A except that the mixture C was used.
- the hardness and disintegration time of the tablet were calculated
- hydroxypropyl cellulose the volume average particle diameter 12 micrometer hydroxypropyl cellulose fine particle L2 obtained by the same method as Example 3 and the volume average particle diameter 12 micrometer hydroxypropyl cellulose fine particle obtained by the same method as Example 4 were used.
- SSL2 and hydroxypropylcellulose bulk HPC L 100-mesh products were used.
- the particle size distribution of the hydroxypropyl cellulose fine particles SSL2 is shown in FIG.
- Example 7 Hydroxypropylcellulose 2.5% by weight, lactose (Freund Sangyo “Dilactose S”) 73.1% by weight, corn starch (Nippon Shokuhin Kako Co., Ltd. “Corn Starch W”) 24.4% by weight, and magnesium stearate 0 Mixture D was obtained by sufficiently mixing 5% by weight (extra). Tablet D was obtained by the same method as the manufacturing method of tablet A except that the mixture D was used. About the said tablet D, the hardness and disintegration time of the tablet were calculated
- hydroxypropylcellulose As hydroxypropylcellulose, hydroxypropylcellulose fine particles SSL2 having a volume average particle diameter of 12 ⁇ m obtained by the same method as in Example 4 were used. It can be seen that a tablet with high hardness and short disintegration time can be obtained by adding a small amount of hydroxypropyl cellulose fine particles SSL2.
- Example 8 5% by weight of hydroxypropyl cellulose, 50% by weight of acetaminophen (fine powder manufactured by Yamamoto Chemical Co., Ltd.), 31.5% by weight of lactose (“Dilactose S” manufactured by Freund Sangyo Co., Ltd.), corn starch (“Corn Starch W” manufactured by Nippon Shokuhin Kako Co., Ltd.) ) 13.5 wt% and magnesium stearate 0.5 wt% (external split) were mixed thoroughly to obtain a mixture E.
- Tablet E was obtained by the same method as the manufacturing method of tablet A except that the mixture E was used. About the said tablet E, the hardness and disintegration time of the tablet were calculated
- hydroxypropylcellulose hydroxypropylcellulose fine particles SL2 having a volume average particle diameter of 13 ⁇ m obtained in the same manner as in Example 2 and 100-mesh passed product of hydroxypropylcellulose bulk HPC SL (volume average particle diameter of 40 ⁇ m; Hereinafter, they are referred to as “SLB”).
- Example 9 10% by weight of hydroxypropylcellulose, 86 parts by weight of glucosamine (“Glucosamine GM” manufactured by Protein Chemical Co., Ltd.) and 4 parts by weight of sugar ester (“S-370F” manufactured by Mitsubishi Chemical Foods Co., Ltd.) are thoroughly mixed to obtain a mixture G It was.
- a tablet G was obtained by the same method as the manufacturing method of the tablet A except that the mixture G was used.
- the hardness and disintegration time of the tablet were calculated
- hydroxypropylcellulose As hydroxypropylcellulose, hydroxypropylcellulose bulk HPC L 100-mesh product (LB) and hydroxypropylcellulose fine particles SSL2 having a volume average particle diameter of 12 ⁇ m obtained in the same manner as in Example 4 were used. It was.
- Example 10 3 parts by weight of hydroxypropylcellulose fine particles SSL2 having a volume average particle diameter of 12 ⁇ m obtained by the same method as in Example 4, 1 part by weight of magnesium stearate (lubricant), 1 part by weight of crospovidone (disintegrant), erythritol A tablet H was obtained by compressing 95 parts by weight with a compression pressure of 200 MPa. Compression pressure of 3 parts by weight of SSL2, 3 parts by weight of sucrose fatty acid ester (“SE, S-170” manufactured by Mitsubishi Chemical Foods) (lubricant), 1 part by weight of crospovidone (disintegrant), and 93 parts by weight of erythritol Tablet I was obtained by tableting at 200 MPa.
- SE sucrose fatty acid ester
- Compression pressure of 2 parts by weight of SSL2, 3 parts by weight of sucrose fatty acid ester (“SE, S-170” manufactured by Mitsubishi Chemical Foods) (lubricant), 1 part by weight of crospovidone (disintegrant), and 94 parts by weight of erythritol Tablet J was obtained by tableting at 200 MPa.
- the tablet was tableted at a compression pressure of 200 MPa to obtain tablet K.
- Table 4 shows the tensile strength, disintegration time, and disintegration time in the oral cavity of tablets H to K.
- “Intraoral disintegration time” is the average of 6 adult men and women who rinsed the oral cavity with distilled water, put one tablet into the oral cavity, and measured the time until complete disintegration without stagnation Value.
- the tensile strength decreased as the hydroxypropyl cellulose fine particle content decreased
- the formulation (tablet K) having a content of 1.5 parts in both parts also showed a tensile strength of 1 MPa.
- the disintegration time was almost the same for all formulations.
- the disintegration time of the tablet K in the oral cavity was about 20 seconds. From the above, it was found that tablets having excellent oral disintegrability can be prepared using hydroxypropyl cellulose fine particles.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
本願は、2009年11月24日に日本に出願された特願2009-266821号及び2010年6月14日に日本に出願された特願2010-135622号に基づき優先権を主張し、その内容をここに援用する。
ヒドロキシアルキルセルロースは、通常、粒子状にして供給される。ヒドロキシプロピルセルロース粒子の調製法としてスプレードライ法が報告されている。スプレードライ法を用いた場合、目的の粒子を得るためには希薄溶液からの粒子調製が必要であり、生産性の点で問題を有していた。また、特許文献1には、貼付剤の粘着層に用いるための、粒子径が1~150μmであるヒドロキシプロピルセルロース粒子が開示されている。また、特許文献2や特許文献3には、固形製剤に用いるための、乾式レーザー回折法により測定される体積平均粒子径が25μm以下の低置換度ヒドロキシプロピルセルロース粒子が開示されている。これらのヒドロキシプロピルセルロース粒子は、振動ミルなどによって得られた粉末を流動層造粒して調製されている。
このような従来のヒドロキシアルキルセルロース粒子は、直接打錠法による錠剤製造における圧縮特性が十分でなく、得られる錠剤の引張強度や崩壊性が必ずしも満足できるものでなかった。
そこで、本発明の一態様は、引張強度や崩壊性に優れた固形製剤を得るのに適したヒドロキシアルキルセルロース微粒子を提供することを課題とする。
〈1〉 パルス衝撃波を発生させ、当該パルス衝撃波の発生領域にヒドロキシアルキルセルロース水溶液を供給してヒドロキシアルキルセルロース水溶液を粉砕乾燥させることを含む、ヒドロキシアルキルセルロース微粒子の製造方法。
〈2〉 前記ヒドロキシアルキルセルロース水溶液の濃度が1~5重量%である前記〈1〉に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈3〉 得られるヒドロキシアルキルセルロース微粒子の形状が球状である前記〈1〉または〈2〉に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈4〉 水溶液として供給されるヒドロキシアルキルセルロースは、その2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、前記〈1〉~〈3〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈5〉 水溶液として供給されるヒドロキシアルキルセルロースは、ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、前記〈1〉~〈4〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈6〉 水溶液として供給されるヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、前記〈1〉~〈5〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈7〉 パルス燃焼器と、その排気管の出口付近に配置される原料供給口と、継続して発生する非線形波動を原料に与えるため、供給された原料の粒子回りにおける前記パルス燃焼器の排気ガスの粒子レイノルズ数を変更可能に設定するガス調整手段を有する粉砕乾燥装置に、原料としてヒドロキシアルキルセルロース水溶液を供給して粉砕乾燥させることを含む、ヒドロキシアルキルセルロース微粒子の製造方法。
〈8〉 前記排気ガスの温度が70~90℃の範囲にある前記〈7〉に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈9〉 前記ヒドロキシアルキルセルロース水溶液の濃度が1~5重量%である前記〈7〉または〈8〉に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈10〉 得られるヒドロキシアルキルセルロース微粒子の形状が球状である前記〈7〉~〈9〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈11〉 水溶液として供給されるヒドロキシアルキルセルロースは、その2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、前記〈7〉~〈10〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈12〉 水溶液として供給されるヒドロキシアルキルセルロースは、ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、前記〈7〉~〈11〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈13〉 水溶液として供給されるヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、前記〈7〉~〈12〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
〈14〉 前記〈1〉~〈6〉のいずれか1項に記載の製造方法で得られるヒドロキシアルキルセルロース微粒子。
〈15〉 前記〈7〉~〈13〉のいずれか1項に記載の製造方法で得られるヒドロキシアルキルセルロース微粒子。
〈16〉 体積平均粒子径が0.1μm以上15μm未満である、ヒドロキシアルキルセルロース微粒子。
〈17〉 前記体積平均粒子径が0.1μm以上10μm未満である、前記〈16〉に記載のヒドロキシアルキルセルロース微粒子。
〈18〉 その形状が球状である、前記〈16〉または〈17〉に記載のヒドロキシアルキルセルロース微粒子。
〈19〉 2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、前記〈16〉~〈18〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
〈20〉 2%水溶液の20℃における粘度が2.0~10.0mPa・sの範囲にある、前記〈16〉~〈18〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
〈21〉 ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、前記〈16〉~〈20〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
〈22〉 ヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、前記〈16〉~〈21〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
〈23〉 固形製剤に用いられる前記〈14〉~〈22〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
〈24〉 前記〈14〉~〈22〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子を含有して成る固形製剤。
〈25〉 前記〈14〉~〈22〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子を含有して成る口腔内崩壊錠。
〈26〉 主薬と、前記〈14〉~〈22〉のいずれか1項に記載のヒドロキシアルキルセルロース微粒子とを混合し、当該混合物を打錠することを含む固形製剤の製造方法。
また、本発明のヒドロキシアルキルセルロース微粒子は、直接打錠法等による錠剤などの固形製剤の製造に好適に用いられる。本発明のヒドロキシアルキルセルロース微粒子を用いて直接打錠法等によって錠剤などの固形製剤を製造すると、固形製剤の引張強度が高くなり、また圧縮圧力のバラツキによる崩壊性のバラツキが非常に小さくなる。また、本発明のヒドロキシアルキルセルロース微粒子を用いると、結合力が高まり固形製剤の崩壊時間を長くすることができるので、製剤に徐放性を付与しやすい。
さらに水溶液として供給されるヒドロキシアルキルセルロースは、2%水溶液の20℃における粘度が、2.0~20.0mPa・sの範囲にあることが好ましく、2.0~10.0mPa・sの範囲にあることがより好ましい。
パルス衝撃波の発生領域に供給されるヒドロキシアルキルセルロース水溶液は、その濃度が、1~30重量%であることが好ましく、1~20重量%であることがより好ましく、1~10重量%であることがさらに好ましく、1~5重量%であることが殊更に好ましい。
農薬としては、例えば、抗菌剤、抗ウイルス剤、殺菌剤、殺ダニ剤、殺虫剤、殺線虫剤、殺鼠剤、除草剤、植物生長調節剤、肥料、薬害軽減剤などが挙げられる。
健康食品用成分としては、健康増強を目的のために配合する成分であれば限定されないが、例えば、青汁粉末、アグリコン、アガリクス、アシュワガンダ、アスタキサンチン、アセロラ、アミノ酸(バリン、ロイシン、イソロイシン、リジン、メチオニン、フェニルアラニン、トレオニン、トリプトファン、ヒスチジン、シスチン、チロシン、アルギニン、アラニン、アスパラギン酸、海藻粉末、グルタミン、グルタミン酸、グリシン、プロリン、セリン等)、アルギン酸、いちょう葉エキス、イワシペプチド、ウコン、ウロン酸、エキナセア、エゾウコギ、オリゴ糖、オレイン酸、核タンパク、カツオブシペプチド、カテキン、カリウム、カルシウム、カロチノイド、ガルシニア、L一カルニチン、キトサン、共役リノール酸、キダチアロエ、ギムネマシルベスタエキス、クエン酸、クミスクチン、グリセリド、グリセノール、グルカゴン、グルタミン、グルコサミン、L一グルタミン、クロレラ、クランベリーエキス、キャッツクロー、ゲルマニウム、酵素、高麗人参エキス、コエンザイムQIO、コラーゲン、コラーゲンペプチド、コリウスフォルスコリン、コンドロイチン、サイリウムハスク末、サンザシエキス、サポニン、脂質、L一シスチン、シソエキス、シトリマックス、脂肪酸、植物ステロール、種子エキス、スピルリナ、スクワレン、セイヨウシロヤナギ、セラミド、セレン、セントジョーンズワートエキス、大豆インフラボン、大豆サポニン、大豆ペプチド、大豆レシチン、単糖、タンパク質、チェストツリーエキス、鉄、銅、ドコサヘキサエン酸、トコトリエノール、納豆キナーゼ、納豆菌培養エキス、ナイアシンナトリウム、ニコチン酸、二糖、乳酸菌、ニンニク、ノコギリヤシ、発芽米、ハトムギエキス、ハーブエキス、バレリヤンエキス、パントテン酸、ヒアルロン酸、ビオチン、ピコリン酸クロム、ビタミンA、A2ビタミンB1、B2、B6、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK、ヒドロキシチロソール、ビフィズス菌、ビール酵母、フラクトオリゴ糖、フラボノイド、ブッチャーズブルームエキス、ブラックコホシュ、ブルーベリー、プルーンエキス、プロアントシアニジン、プロテイン、プロポリス、ブロメライン、プロバイオティクス、ホスファチジルコリン、ホスファチジルセリン、β一カロチン、ペプチド、ベニバナエキス、マイタケエキス、マカエキス、マグネシウム、マリアアザミ、マンガン、ミトコンドリア、ミネラル、ムコ多糖、メラトニン、メシマコブ、メリロートエキス末、モリブデン、野菜粉末、葉酸、ラクトース、リコピン、リノール酸、リポ酸、燐(リン)、ルテイン、レシチン、ロズマリン酸、ローヤルゼリー、DHA、EPA等が挙げられる。
糖衣基剤としては、白糖が用いられ、さらに、タルク、沈降炭酸カルシウム、リン酸カルシウム、硫酸カルシウム、ゼラチン、アラビアゴム、ポリビニルピロリドン、プルラン等があげられる。
水溶性フィルムコーティング基剤としては、例えば、ポリビニルアルコール、ポリビニルアルコール-ポリエチレングリコールグラフトコポリマー、ポリビニルアルコール-アクリル酸-メタクリル酸メチルコポリマー、ポリビニルアセタールジエチルアミノアセテート、アミノアルキルメタクリレートコポリマー、ポリビニルピロリドン、マクロゴールなどの合成高分子;プルランなどの多糖類等が挙げられる。
腸溶性フィルムコーティング基剤としては、例えば、メタアクリル酸コポリマーL、メタアクリル酸コポリマーLD、メタアクリル酸コポリマーSなどのアクリル酸誘導体;セラックなどの天然物等が挙げられる。
徐放性フィルムコーティング基剤としては、例えば、アミノアルキルメタクリレートコポリマーRS、アクリル酸エチル・メタクリル酸メチル・共重合体乳濁液などのアクリル酸誘導体等が挙げられる。
ヒドロキシプロピルセルロース微粒子または原末10重量%、シリカ(富士シリシア化学社製「サイリシア350」)0.5重量%、ステアリン酸マグネシウム1重量%、およびエリスリトール88.5重量%を十分に混合して合剤Aを得た。
EE/CE(%)=〔(Expansion Energy)/(Cycle Energy)〕×100
図9に示すBの領域がEEに相当し、AとBとを合わせた領域がCEに相当する。
ln(1/(1-D)) = K×P + A
Dは、見かけの相対密度; Pは、圧縮圧力(MPa); Kは、x軸を圧縮圧P、y軸をln(1/(1-D))として、データをプロットしたときに描かれる直線部の傾き;およびAは、前記直線部を外挿したときの圧縮圧力P=0MPaにおける値(すなわち、外挿線のy軸切片)である。降伏圧は1/Kで算出される。
TS=2P/(πDT)
TSは錠剤の引張強度(MPa)、Pは錠剤の硬度(N)、πは円周率、Dは錠剤の直径(mm)、およびTは錠剤の厚さ(mm)である。
日本薬局方に適合するヒドロキシプロピルセルロース原末(2%水溶液の20℃における粘度6.0~10.0mPa・s;日本曹達社製「HPC L」)を水に溶かして、1%、2%、5%、および10%水溶液をそれぞれ得た。なお、ヒドロキシプロピルセルロースHPC Lの原末は体積平均粒子径103.6μmで不定形状をしていた(図12を参照)。
パルス燃焼器を有する粉砕乾燥装置(大川原化工機社製「ハイパルコン」)に前記ヒドロキシプロピルセルロース水溶液を供給し、当該水溶液にパルスジェットを与えて粉砕乾燥を行った。前記水溶液が供給される領域における排気ガス温度は80℃に設定した。
この粉砕乾燥によって、ヒドロキシプロピルセルロース微粒子が得られた。これらの微粒子はいずれも若干扁平した球形であった(図13を参照)。微粒子の粒子径D16、D50、およびD84は、表1に示すとおりであった。得られたヒドロキシプロピルセルロース微粒子の2%水溶液の20℃における粘度は、いずれも原末と同じであったことから、乾燥過程においてヒドロキシプロピルセルロース自身の熱劣化が無かったことがわかる。
実施例1におけるヒドロキシプロピルセルロース2%水溶液をヒドロキシプロピルセルロース(2%水溶液の20℃における粘度3.0~5.9mPa・s;日本曹達社製「HPC SL」)の2%水溶液に替えた以外は実施例1と同じ手法にてヒドロキシプロピルセルロース微粒子を得た。当該微粒子の粒子径D16、D50、およびD84は、表2に示すとおりであった。この微粒子は若干扁平した球形であった。微粒子の2%水溶液の20℃における粘度は原末と同じであった。なお、ヒドロキシプロピルセルロースHPC SLの原末は体積平均粒子径83.3μmで角張った異形状をしていた。
ヒドロキシプロピルセルロース(2%水溶液の20℃における粘度6.0~10.0mPa・s;日本曹達社製「HPC L」)の10%および20%水溶液を用いた以外は実施例1と同じ手法にてヒドロキシプロピルセルロース微粒子を得た。当該微粒子の粒子径D16、D50、およびD84は、表2に示すとおりであった。これらの微粒子は若干扁平した球形であった(図14および図15を参照)。微粒子の2%水溶液の20℃における粘度は原末と同じであった。
実施例3におけるヒドロキシプロピルセルロース20%水溶液をヒドロキシプロピルセルロース(2%水溶液の20℃における粘度2.0~2.9mPa・s;日本曹達社製「HPC SSL」)の20%水溶液に替えた以外は実施例3と同じ手法にてヒドロキシプロピルセルロース微粒子を得た。当該微粒子の粒子径D16、D50、およびD84は、表3に示すとおりであった。この微粒子は若干扁平した球形であった(図16を参照)。微粒子の2%水溶液の20℃における粘度は原末と同じであった。なお、ヒドロキシプロピルセルロースHPC SSLの原末は角張った異形状をしていた。
ヒドロキシプロピルセルロース(2%水溶液の20℃における粘度6.0~10.0mPa・s;日本曹達社製「HPC L」)の1%水溶液を、スプレードライ法によって150℃で乾燥させた。この乾燥によって、ヒドロキシプロピルセルロースSD1が得られた。このSD1の形状は図17に示すようなものであった。SD1の粒子径D16、D50、およびD84は、表3に示すとおりであった。
水溶液濃度を2%に変え且つスプレードライ法における乾燥温度を180℃に変えた以外は、比較例1と同じ手法でヒドロキシプロピルセルロースSD2を得た。このSD2の形状は図18に示すようなものであった。SD2の粒子径は、D16、D50、およびD84は、表3に示すとおりであった。
また、図3および図4から、本発明のヒドロキシプロピルセルロース微粒子(LMまたはSLM)を用いた錠剤は、引張強度が高く、崩壊時間が長くなることがわかる。特に2%水溶液の20℃における粘度が3.0~5.9mPa・sであるヒドロキシプロピルセルロースを用いた、SLとSLMとの対比では、崩壊時間に顕著な差が現れた。
さらに、図7に示すように、従来の一般的乾燥法であるスプレードライ法で得たヒドロキシプロピルセルロース(SD2)を用いた錠剤は、原末をそのまま用いた錠剤に比べて引張強度が高くなっているものの、本発明のヒドロキシプロピルセルロース微粒子(LM)を用いた錠剤に比べると引張強度がかなり低いことがわかる。
図8および図9に示すように、2%水溶液の20℃における粘度や、粉砕乾燥に供給する水溶液の濃度によって、錠剤の強度や崩壊時間を調整できることがわかる。
ヒドロキシプロピルセルロース微粒子(LM)3重量%、シリカ(富士シリシア化学社製「サイリシア350」)0.5重量%、ステアリン酸マグネシウム1重量%、クロスポビドン(崩壊剤)10重量%、15重量%および20重量%、ならびにエリスリトール85.5重量%、80.5重量%および75.5重量%を十分に混合して合剤B-1、B-2およびB-3をそれぞれ得た。
前記合剤B-1、B-2およびB-3を用いた以外は錠剤Aの製造方法と同じ手法にて錠剤B-1、B-2およびB-3をそれぞれ得た。当該錠剤について、上記と同じ手法にて錠剤の引張強度を求めた。その結果を図10に示す。崩壊剤の添加によって、引張強度がさらに高くなることがわかる。また、前記合剤B-1、B-2およびB-3は、いずれも上記崩壊試験による崩壊時間が30秒以内であった。
ヒドロキシプロピルセルロース10重量%、乳糖(フロイント産業社製「ダイラクトースS」)63重量%、コーンスターチ(日本食品化工社製「コーンスターチW」)27重量%、及びステアリン酸マグネシウム0.5重量%(外割り)を十分に混合して合剤Cを得た。合剤Cを用いた以外は錠剤Aの製造方法と同じ手法にて錠剤Cを得た。当該錠剤Cについて、上記と同じ手法にて錠剤の硬度および崩壊時間を求めた。それらの結果を図19に示す。
なお、ヒドロキシプロピルセルロースとしては、実施例3と同じ手法で得られた体積平均粒子径12μmのヒドロキシプロピルセルロース微粒子L2、実施例4と同じ手法で得られた体積平均粒子径12μmのヒドロキシプロピルセルロース微粒子SSL2、およびヒドロキシプロピルセルロース原末HPC Lの100メッシュ通過品(体積平均粒子径44μm;以下、「LB」と表記する。)をそれぞれ用いた。ヒドロキシプロピルセルロース微粒子SSL2の粒径分布を図20に示す。
ヒドロキシプロピルセルロース2.5重量%、乳糖(フロイント産業社製「ダイラクトースS」)73.1重量%、コーンスターチ(日本食品化工社製「コーンスターチW」)24.4重量%、及びステアリン酸マグネシウム0.5重量%(外割り)を十分に混合して合剤Dを得た。合剤Dを用いた以外は錠剤Aの製造方法と同じ手法にて錠剤Dを得た。当該錠剤Dについて、上記と同じ手法にて錠剤の硬度および崩壊時間を求めた。それらの結果を図19に示す。
なお、ヒドロキシプロピルセルロースとしては、実施例4と同じ手法で得られた体積平均粒子径12μmのヒドロキシプロピルセルロース微粒子SSL2を用いた。ヒドロキシプロピルセルロース微粒子SSL2を少量添加することによって、高い硬度で且つ短い崩壊時間の錠剤が得られることがわかる。
ヒドロキシプロピルセルロース5重量%、アセトアミノフェン(山本化学社製 微粉)50重量%、乳糖(フロイント産業社製「ダイラクトースS」)31.5重量%、コーンスターチ(日本食品化工社製「コーンスターチW」)13.5重量%、及びステアリン酸マグネシウム0.5重量%(外割り)を十分に混合して合剤Eを得た。合剤Eを用いた以外は錠剤Aの製造方法と同じ手法にて錠剤Eを得た。当該錠剤Eについて、上記と同じ手法にて錠剤の硬度および崩壊時間を求めた。それらの結果を図21に示す。
なお、ヒドロキシプロピルセルロースとしては、実施例2と同じ手法で得られた体積平均粒子径13μmのヒドロキシプロピルセルロース微粒子SL2、およびヒドロキシプロピルセルロース原末HPC SLの100メッシュ通過品(体積平均粒子径40μm;以下、「SLB」と表記する。)をそれぞれ用いた。
アセトアミノフェン(山本化学社製、微粉)50重量%、乳糖(フロイント産業社製「ダイラクトースS」)35重量%、コーンスターチ(日本食品化工社製「コーンスターチW」)15重量%、及びステアリン酸マグネシウム0.5重量%(外割り)を十分に混合して合剤Fを得た。合剤Fを用いた以外は錠剤Aの製造方法と同じ手法にて錠剤Eを得た。当該錠剤Fについて、上記と同じ手法にて錠剤の硬度および崩壊時間を求めた。結合剤無しの結果を図21に示す。
ヒドロキシプロピルセルロース10重量%、グルコサミン(プロテインケミカル社製「グルコサミンGM」)86重量部、シュガーエステル(三菱化学フーズ社製「S-370F」)4重量部を十分に混合して合剤Gを得た。合剤Gを用いた以外は錠剤Aの製法と同じ手法にて錠剤Gを得た。当該錠剤Gについて、上記と同じ手法にて錠剤の硬度および崩壊時間を求めた。それらの結果を図22に示す。
なお、ヒドロキシプロピルセルロースとしては、ヒドロキシプロピルセルロース原末HPC Lの100メッシュ通過品(LB)、および、実施例4と同じ手法で得られた体積平均粒子径12μmのヒドロキシプロピルセルロース微粒子SSL2をそれぞれ用いた。
実施例4と同じ手法で得られた体積平均粒子径12μmのヒドロキシプロピルセルロース微粒子SSL2を3重量部、ステアリン酸マグネシウム(滑沢剤)を1重量部、クロスポビドン(崩壊剤)1重量部、エリスリトール95重量部を圧縮圧力200MPaで打錠して錠剤Hを得た。SSL2を3重量部、ショ糖脂肪酸エステル(三菱化学フーズ社製「SE,S-170」)(滑沢剤)3重量部、クロスポビドン(崩壊剤)1重量部、エリスリトール93重量部を圧縮圧力200MPaで打錠して錠剤Iを得た。SSL2を2重量部、ショ糖脂肪酸エステル(三菱化学フーズ社製「SE,S-170」)(滑沢剤)3重量部、クロスポビドン(崩壊剤)1重量部、エリスリトール94重量部を圧縮圧力200MPaで打錠して錠剤Jを得た。SSL2を1.5重量部、ショ糖脂肪酸エステル(三菱化学フーズ社製「SE,S-170」)(滑沢剤)3重量部、クロスポビドン(崩壊剤)1重量部、エリスリトール94.5重量部を圧縮圧力200MPaで打錠して錠剤Kを得た。
錠剤H~Kの引張強度、崩壊時間、口腔内での崩壊時間は表4に示すとおりであった。「口腔内での崩壊時間」とは、成人男女6名が、口腔内を蒸留水ですすいだ後、錠剤を一つ口腔内へふくみ、かまずに完全に崩壊するまでの時間を測定した平均値である。
ヒドロキシプロピルセルロース微粒子含量が減少するにつれて引張強度は減少したが、含量が1.5重両部の処方(錠剤K)においても1MPaの引張強度を示した。崩壊時間はいずれの処方でもほぼ同程度の値を示した。また、錠剤Kの口腔内での崩壊時間は20秒程度であった。以上より、ヒドロキシプロピルセルロース微粒子を用いて口腔内崩壊性にすぐれた錠剤を調製可能であることが判った。
Claims (26)
- 体積平均粒子径が0.1μm以上15μm未満である、ヒドロキシアルキルセルロース微粒子。
-
前記体積平均粒子径が0.1μm以上10μm未満である、請求項1に記載のヒドロキシアルキルセルロース微粒子。 - その形状が球状である、請求項1または2に記載のヒドロキシアルキルセルロース微粒子。
- 2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、請求項1~3のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
- 2%水溶液の20℃における粘度が2.0~10.0mPa・sの範囲にある、請求項1~3のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
- ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、請求項1~5のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
- ヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、請求項1~6のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
- 固形製剤に用いられる請求項1~7のいずれか1項に記載のヒドロキシアルキルセルロース微粒子。
- パルス衝撃波を発生させ、当該パルス衝撃波の発生領域にヒドロキシアルキルセルロース水溶液を供給してヒドロキシアルキルセルロース水溶液を粉砕乾燥させることを含む、ヒドロキシアルキルセルロース微粒子の製造方法。
- 前記ヒドロキシアルキルセルロース水溶液の濃度が1~5重量%である請求項9に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 得られるヒドロキシアルキルセルロース微粒子の形状が球状である請求項9または10に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースは、その2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、請求項9~11のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースは、ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、請求項9~12のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、請求項9~13のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- パルス燃焼器と、その排気管の出口付近に配置される原料供給口と、継続して発生する非線形波動を原料に与えるため、供給された原料の粒子回りにおける前記パルス燃焼器の排気ガスの粒子レイノルズ数を変更可能に設定するガス調整手段を有する粉砕乾燥装置に、原料としてヒドロキシアルキルセルロース水溶液を供給して粉砕乾燥させることを含む、ヒドロキシアルキルセルロース微粒子の製造方法。
- 前記排気ガスの温度が70~90℃の範囲にある請求項15に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 前記ヒドロキシアルキルセルロース水溶液の濃度が1~5重量%である請求項15または16に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 得られるヒドロキシアルキルセルロース微粒子の形状が球状である請求項15~17のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースは、その2%水溶液の20℃における粘度が2.0~20.0mPa・sの範囲にある、請求項15~18のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースは、ヒドロキシアルキル基の含有量が40~80重量%の範囲にある、請求項15~19のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 水溶液として供給されるヒドロキシアルキルセルロースがヒドロキシプロピルセルロースである、請求項15~20のいずれか1項に記載のヒドロキシアルキルセルロース微粒子の製造方法。
- 請求項9~14のいずれか1項に記載の製造方法で得られるヒドロキシアルキルセルロース微粒子。
- 請求項15~21のいずれか1項に記載の製造方法で得られるヒドロキシアルキルセルロース微粒子。
- 請求項1~7、22および23のいずれか1項に記載のヒドロキシアルキルセルロース微粒子を含有して成る固形製剤。
- 請求項1~7、22および23のいずれか1項に記載のヒドロキシアルキルセルロース微粒子を含有して成る口腔内崩壊錠。
- 主薬と、請求項1~7、22および23のいずれか1項に記載のヒドロキシアルキルセルロース微粒子とを混合し、当該混合物を打錠することを含む固形製剤の製造方法。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080052422.3A CN102666590B (zh) | 2009-11-24 | 2010-11-24 | 羟烷基纤维素微粒 |
JP2011543254A JPWO2011065350A1 (ja) | 2009-11-24 | 2010-11-24 | ヒドロキシアルキルセルロース微粒子 |
KR1020127012768A KR101450979B1 (ko) | 2009-11-24 | 2010-11-24 | 하이드록시알킬 셀룰로오스 미립자 |
US13/510,096 US8568787B2 (en) | 2009-11-24 | 2010-11-24 | Hydroxyalkylcellulose microparticles |
ES10833196.8T ES2656522T3 (es) | 2009-11-24 | 2010-11-24 | Micropartículas de hidroxialquilcelulosa |
EP10833196.8A EP2492284B1 (en) | 2009-11-24 | 2010-11-24 | Hydroxyalkylcellulose microparticles |
SI201031618T SI2492284T1 (en) | 2009-11-24 | 2010-11-24 | HYDROXYCARCULULOSE MICROELECTRONICS |
US14/021,995 US9090714B2 (en) | 2009-11-24 | 2013-09-09 | Method of making hydroxyalkylcellulose microparticles |
HRP20180035TT HRP20180035T1 (hr) | 2009-11-24 | 2018-01-09 | Mikročestice od hidroksalkilceluloze |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-266821 | 2009-11-24 | ||
JP2009266821 | 2009-11-24 | ||
JP2010135622 | 2010-06-14 | ||
JP2010-135622 | 2010-06-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/510,096 A-371-Of-International US8568787B2 (en) | 2009-11-24 | 2010-11-24 | Hydroxyalkylcellulose microparticles |
US14/021,995 Division US9090714B2 (en) | 2009-11-24 | 2013-09-09 | Method of making hydroxyalkylcellulose microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011065350A1 true WO2011065350A1 (ja) | 2011-06-03 |
Family
ID=44066455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/070867 WO2011065350A1 (ja) | 2009-11-24 | 2010-11-24 | ヒドロキシアルキルセルロース微粒子 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8568787B2 (ja) |
EP (1) | EP2492284B1 (ja) |
JP (2) | JPWO2011065350A1 (ja) |
KR (1) | KR101450979B1 (ja) |
CN (1) | CN102666590B (ja) |
ES (1) | ES2656522T3 (ja) |
HR (1) | HRP20180035T1 (ja) |
HU (1) | HUE035786T2 (ja) |
PT (1) | PT2492284T (ja) |
SI (1) | SI2492284T1 (ja) |
TW (1) | TWI400089B (ja) |
WO (1) | WO2011065350A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013047353A1 (ja) | 2011-09-26 | 2013-04-04 | 日本曹達株式会社 | ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠 |
EP2907508A1 (en) | 2014-02-14 | 2015-08-19 | Shin-Etsu Chemical Co., Ltd. | Hydroxyalkylalkyl cellulose for tableting and solid preparation comprising the same |
EP3011956A1 (en) | 2014-10-23 | 2016-04-27 | Shin-Etsu Chemical Co., Ltd. | Alkyl cellulose for use in tableting and solid preparation comprising same |
WO2017094569A1 (ja) * | 2015-11-30 | 2017-06-08 | 旭化成株式会社 | セルロース、無機化合物及びヒドロキシプロピルセルロースを含む複合粒子 |
EP3216463A1 (en) | 2016-03-09 | 2017-09-13 | Shin-Etsu Chemical Co., Ltd. | Solid preparation containing alkyl cellulose and method for producing the same |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX337827B (es) * | 2011-04-06 | 2016-03-22 | Dow Global Technologies Llc | Novedosos derivados polisacaridos y formas de administracion. |
CN103156878A (zh) * | 2013-04-11 | 2013-06-19 | 天津市园艺工程研究所 | 一种桑黃多糖opc缓释微囊 |
GB201323132D0 (en) * | 2013-12-30 | 2014-02-12 | Mihranyan Albert | New products and processes |
CN106687855A (zh) * | 2014-10-16 | 2017-05-17 | 堺显示器制品株式会社 | 显示装置 |
CN113164396B (zh) * | 2018-11-26 | 2023-11-03 | 宝洁公司 | 含有硫辛酸的固体药物制剂及其用途 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01152103A (ja) * | 1987-12-08 | 1989-06-14 | Nippon Soda Co Ltd | セルロース誘導体球状粒子およびその製造方法 |
JPH0770203A (ja) * | 1993-08-31 | 1995-03-14 | Shin Etsu Chem Co Ltd | セルロース誘導体の微粉砕化方法 |
JPH08100001A (ja) * | 1994-09-28 | 1996-04-16 | Teijin Ltd | 蛍光標識化セルロース類 |
JPH09143080A (ja) * | 1995-11-22 | 1997-06-03 | Takada Seiyaku Kk | 水酸化アルミニウム・水酸化マグネシウム含有固形製剤 |
JP2000212068A (ja) * | 1999-01-18 | 2000-08-02 | Gruenenthal Gmbh | 薬学的有効物質90重量%まで含有するペレットの製造方法。 |
JP2001200001A (ja) * | 1999-11-09 | 2001-07-24 | Shin Etsu Chem Co Ltd | 低置換度ヒドロキシプロピルセルロース及びその製造方法 |
JP2001322927A (ja) * | 2000-05-12 | 2001-11-20 | Shin Etsu Chem Co Ltd | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 |
JP2006090571A (ja) * | 2004-09-21 | 2006-04-06 | Kyoto Univ | 粉砕乾燥方法および粉砕乾燥装置 |
JP2007176869A (ja) * | 2005-12-28 | 2007-07-12 | Univ Meijo | 難溶性薬物含有微細粒子 |
JP2007211006A (ja) * | 2006-01-16 | 2007-08-23 | Ono Pharmaceut Co Ltd | 溶出安定性を有するコーティング固形製剤 |
WO2007123187A1 (ja) * | 2006-04-20 | 2007-11-01 | Itoham Foods Inc. | コンフォメーション病医薬組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0633939A (ja) | 1992-07-15 | 1994-02-08 | Enomoto:Kk | 直動機械要素 |
JP3276188B2 (ja) | 1993-01-08 | 2002-04-22 | 積水化学工業株式会社 | 貼付剤及びその製造方法 |
JPH11322584A (ja) * | 1998-05-07 | 1999-11-24 | Sawai Pharmaceutical Co Ltd | ベザフィブラート徐放性製剤 |
US6602994B1 (en) * | 1999-02-10 | 2003-08-05 | Hercules Incorporated | Derivatized microfibrillar polysaccharide |
US6680069B1 (en) * | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
JP2002207030A (ja) | 2001-01-09 | 2002-07-26 | Nippon Soda Co Ltd | ヒドロキシプロピル基含量測定方法及び装置 |
JP4082656B2 (ja) * | 2002-03-04 | 2008-04-30 | 信越化学工業株式会社 | 低置換度セルロースエーテル粉末とその製造方法 |
ES2557165T3 (es) * | 2006-04-12 | 2016-01-22 | Nippon Soda Co., Ltd. | Método para producir una tableta de liberación sostenida |
JP5258223B2 (ja) | 2006-08-08 | 2013-08-07 | 信越化学工業株式会社 | 腸溶性固体分散体の固形製剤及びその製造方法 |
US8778392B2 (en) * | 2007-03-13 | 2014-07-15 | Dainippon Sumitomo Pharma Co., Ltd. | Oral disintegrating tablet |
-
2010
- 2010-11-23 TW TW099140331A patent/TWI400089B/zh active
- 2010-11-24 US US13/510,096 patent/US8568787B2/en active Active
- 2010-11-24 JP JP2011543254A patent/JPWO2011065350A1/ja active Pending
- 2010-11-24 EP EP10833196.8A patent/EP2492284B1/en active Active
- 2010-11-24 ES ES10833196.8T patent/ES2656522T3/es active Active
- 2010-11-24 CN CN201080052422.3A patent/CN102666590B/zh active Active
- 2010-11-24 KR KR1020127012768A patent/KR101450979B1/ko active IP Right Grant
- 2010-11-24 PT PT108331968T patent/PT2492284T/pt unknown
- 2010-11-24 HU HUE10833196A patent/HUE035786T2/hu unknown
- 2010-11-24 SI SI201031618T patent/SI2492284T1/en unknown
- 2010-11-24 WO PCT/JP2010/070867 patent/WO2011065350A1/ja active Application Filing
-
2013
- 2013-09-09 US US14/021,995 patent/US9090714B2/en active Active
-
2014
- 2014-12-01 JP JP2014243228A patent/JP6081436B2/ja active Active
-
2018
- 2018-01-09 HR HRP20180035TT patent/HRP20180035T1/hr unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01152103A (ja) * | 1987-12-08 | 1989-06-14 | Nippon Soda Co Ltd | セルロース誘導体球状粒子およびその製造方法 |
JPH0770203A (ja) * | 1993-08-31 | 1995-03-14 | Shin Etsu Chem Co Ltd | セルロース誘導体の微粉砕化方法 |
JPH08100001A (ja) * | 1994-09-28 | 1996-04-16 | Teijin Ltd | 蛍光標識化セルロース類 |
JPH09143080A (ja) * | 1995-11-22 | 1997-06-03 | Takada Seiyaku Kk | 水酸化アルミニウム・水酸化マグネシウム含有固形製剤 |
JP2000212068A (ja) * | 1999-01-18 | 2000-08-02 | Gruenenthal Gmbh | 薬学的有効物質90重量%まで含有するペレットの製造方法。 |
JP2001200001A (ja) * | 1999-11-09 | 2001-07-24 | Shin Etsu Chem Co Ltd | 低置換度ヒドロキシプロピルセルロース及びその製造方法 |
JP2001322927A (ja) * | 2000-05-12 | 2001-11-20 | Shin Etsu Chem Co Ltd | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 |
JP2006090571A (ja) * | 2004-09-21 | 2006-04-06 | Kyoto Univ | 粉砕乾燥方法および粉砕乾燥装置 |
JP2007176869A (ja) * | 2005-12-28 | 2007-07-12 | Univ Meijo | 難溶性薬物含有微細粒子 |
JP2007211006A (ja) * | 2006-01-16 | 2007-08-23 | Ono Pharmaceut Co Ltd | 溶出安定性を有するコーティング固形製剤 |
WO2007123187A1 (ja) * | 2006-04-20 | 2007-11-01 | Itoham Foods Inc. | コンフォメーション病医薬組成物 |
Non-Patent Citations (3)
Title |
---|
AYAKO SAKA ET AL.: "Funmu Kanso HPC o Ketsugozai to shite Mochiita Chokusetsu Dajo", SEIZAI TO RYUSHI SEKKEI SYMPOSIUM KOEN YOSHISHU, vol. 23, 2006, pages 183 - 186 * |
SHIN'ICHIRO YASUI ET AL.: "Nan'yosei Yakubutsu Pranlukast Suiwabutsu no Yokaisei no Kaizen -Pulse Nensho Kanso System o Mochiiru Baai", DAI 22 KAI SEIZAI TO RYUSHI SEKKEI SYMPOSIUM KOEN YOSHISHU, 21 October 2005 (2005-10-21), pages 232 - 235 * |
YOSHIAKI KAWASHIMA ET AL.: "Control Release Kizai to shite no Bifunka Teichikando Hydroxypropyl Cellulose (L-HPC) no Shisshiki Zoryu ni yoru Joho Seino Henka", JOURNAL OF THE SOCIETY OF POWDER TECHNOLOGY, vol. 29, no. 6, 1992, JAPAN, pages 456 - 459 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364429B2 (en) | 2011-09-26 | 2016-06-14 | Nippon Soda Co., Ltd. | Orally disintegrating tablet containing hydroxyalkyl cellulose microparticles |
KR20140051433A (ko) * | 2011-09-26 | 2014-04-30 | 닛뽕소다 가부시키가이샤 | 히드록시알킬셀룰로오스 미립자를 함유하는 구강내 붕괴정 |
CN103826660A (zh) * | 2011-09-26 | 2014-05-28 | 日本曹达株式会社 | 含有羟烷基纤维素微粒的口腔内崩解片 |
US20140356427A1 (en) * | 2011-09-26 | 2014-12-04 | Nippon Soda Co., Ltd. | Orally disintegrating tablet containing hydroxyalkyl cellulose microparticles |
JPWO2013047353A1 (ja) * | 2011-09-26 | 2015-03-26 | 日本曹達株式会社 | ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠 |
KR20160019971A (ko) | 2011-09-26 | 2016-02-22 | 닛뽕소다 가부시키가이샤 | 히드록시알킬셀룰로오스 미립자를 함유하는 구강내 붕괴정 |
WO2013047353A1 (ja) | 2011-09-26 | 2013-04-04 | 日本曹達株式会社 | ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠 |
KR101886938B1 (ko) * | 2011-09-26 | 2018-08-08 | 닛뽕소다 가부시키가이샤 | 히드록시알킬셀룰로오스 미립자를 함유하는 구강내 붕괴정 |
EP2907508A1 (en) | 2014-02-14 | 2015-08-19 | Shin-Etsu Chemical Co., Ltd. | Hydroxyalkylalkyl cellulose for tableting and solid preparation comprising the same |
KR20150096327A (ko) | 2014-02-14 | 2015-08-24 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 타정용 히드록시알킬알킬셀룰로오스 및 이것을 포함하는 고형 제제 |
EP3011956A1 (en) | 2014-10-23 | 2016-04-27 | Shin-Etsu Chemical Co., Ltd. | Alkyl cellulose for use in tableting and solid preparation comprising same |
US9713593B2 (en) | 2014-10-23 | 2017-07-25 | Shin-Etsu Chemical Co., Ltd. | Alkyl cellulose for use in tableting and solid preparation comprising same |
KR20160047992A (ko) | 2014-10-23 | 2016-05-03 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 타정용 알킬셀룰로오스 및 이것을 포함하는 고형 제제 |
US10058509B2 (en) | 2014-10-23 | 2018-08-28 | Shin-Etsu Chemical Co., Ltd. | Alkyl cellulose for use in tableting and solid preparation comprising same |
US10532029B2 (en) | 2014-10-23 | 2020-01-14 | Shin-Etsu Chemical Co., Ltd. | Alkyl cellulose for use in tableting and solid preparation comprising same |
WO2017094569A1 (ja) * | 2015-11-30 | 2017-06-08 | 旭化成株式会社 | セルロース、無機化合物及びヒドロキシプロピルセルロースを含む複合粒子 |
US10426838B2 (en) | 2015-11-30 | 2019-10-01 | Asahi Kasei Kabushiki Kaisha | Composite particles including cellulose, inorganic compound, and hydroxypropyl cellulose |
EP3216463A1 (en) | 2016-03-09 | 2017-09-13 | Shin-Etsu Chemical Co., Ltd. | Solid preparation containing alkyl cellulose and method for producing the same |
US10696751B2 (en) | 2016-03-09 | 2020-06-30 | Shin-Etsu Chemical Co., Ltd. | Solid preparation containing alkyl cellulose and method for producing the same |
Also Published As
Publication number | Publication date |
---|---|
EP2492284B1 (en) | 2017-12-06 |
HRP20180035T1 (hr) | 2018-03-23 |
ES2656522T3 (es) | 2018-02-27 |
CN102666590A (zh) | 2012-09-12 |
CN102666590B (zh) | 2015-02-18 |
US8568787B2 (en) | 2013-10-29 |
TW201124158A (en) | 2011-07-16 |
US20140034760A1 (en) | 2014-02-06 |
JPWO2011065350A1 (ja) | 2013-04-11 |
KR101450979B1 (ko) | 2014-10-15 |
SI2492284T1 (en) | 2018-04-30 |
TWI400089B (zh) | 2013-07-01 |
JP2015071783A (ja) | 2015-04-16 |
US9090714B2 (en) | 2015-07-28 |
KR20120073342A (ko) | 2012-07-04 |
PT2492284T (pt) | 2018-01-30 |
JP6081436B2 (ja) | 2017-02-15 |
EP2492284A1 (en) | 2012-08-29 |
EP2492284A4 (en) | 2013-11-06 |
US20120232167A1 (en) | 2012-09-13 |
HUE035786T2 (hu) | 2018-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6081436B2 (ja) | ヒドロキシアルキルセルロース微粒子 | |
JP5995284B2 (ja) | 固形製剤 | |
ES2564056T3 (es) | Método para hacer pastillas de cetirizina | |
JP2010070576A (ja) | 速溶解性錠剤 | |
KR20030081489A (ko) | 당알콜을 함유하는 분무건조 분말의 용도 | |
JP5717424B2 (ja) | コーティング粒子 | |
JP2016053079A (ja) | 錠剤及びその製造方法 | |
KR20160019971A (ko) | 히드록시알킬셀룰로오스 미립자를 함유하는 구강내 붕괴정 | |
JP2013087170A (ja) | ヒドロキシプロピルセルロース微粒子 | |
JP7414668B2 (ja) | ポリビニルアルコール含有造粒物及び固形製剤 | |
JP7145121B2 (ja) | 錠剤の製造方法 | |
EP2793856B1 (en) | Orally-disintegrating formulations of flurbiprofen | |
JP2015020964A (ja) | ヒドロキシプロピルセルロース |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080052422.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10833196 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011543254 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13510096 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20127012768 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4472/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010833196 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |